Role of the KEAP1-NRF2 Axis in Renal Cell Carcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Nov 25

PMID 33233657

Citations 13

Authors

Sara Clerici

Alessandra Boletta

Affiliations

Soon will be listed here.

Abstract

NRF2 is a transcription factor that coordinates the antioxidant response in many different tissues, ensuring cytoprotection from endogenous and exogenous stress stimuli. In the kidney, its function is essential in appropriate cellular response to oxidative stress, however its aberrant activation supports progression, metastasis, and resistance to therapies in renal cell carcinoma, similarly to what happens in other nonrenal cancers. While at the moment direct inhibitors of NRF2 are not available, understanding the molecular mechanisms that regulate its hyperactivation in specific tumor types is crucial as it may open new therapeutic perspectives. Here, we focus our attention on renal cell carcinoma, describing how NRF2 hyperactivation can contribute to tumor progression and chemoresistance. Furthermore, we highlight the mechanism whereby the many pathways that are generally altered in these tumors converge to dysregulation of the KEAP1-NRF2 axis.

Citing Articles

Oxidative stress and NRF2 signaling in kidney injury.

Ng C, Kim M, Yanti , Kwak M Toxicol Res. 2025; 41(2):131-147.

PMID: 40013079 PMC: 11850685. DOI: 10.1007/s43188-024-00272-x.

Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma.

Li J, Huang K, Thakur M, McBride F, Sadagopan A, Gallant D Nat Metab. 2025; .

PMID: 39915638 DOI: 10.1038/s42255-025-01218-9.

Nrf2 Signaling in Renal Cell Carcinoma: A Potential Candidate for the Development of Novel Therapeutic Strategies.

Schiavoni V, Emanuelli M, Milanese G, Galosi A, Pompei V, Salvolini E Int J Mol Sci. 2025; 25(24.

PMID: 39769005 PMC: 11675435. DOI: 10.3390/ijms252413239.

Toward a CRISPR-based mouse model of -deficient clear cell kidney cancer: Initial experience and lessons learned.

Stransky L, Gao W, Schmidt L, Bi K, Ricketts C, Ramesh V Proc Natl Acad Sci U S A. 2024; 121(41):e2408549121.

PMID: 39365820 PMC: 11474080. DOI: 10.1073/pnas.2408549121.

HADH suppresses clear cell renal cell carcinoma progression through reduced NRF2-dependent glutathione synthesis.

Chu C, Liu S, He Z, Wu M, Xia J, Zeng H Transl Oncol. 2024; 49:102112.

PMID: 39226735 PMC: 11402447. DOI: 10.1016/j.tranon.2024.102112.

References

Ying G, Wu R, Xia M, Fei X, He Q, Zha C . Identification of eight key miRNAs associated with renal cell carcinoma: A meta-analysis. Oncol Lett. 2018; 16(5):5847-5855. PMC: 6176358. DOI: 10.3892/ol.2018.9384. View

Jain A, Jaiswal A . GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem. 2007; 282(22):16502-10. DOI: 10.1074/jbc.M611336200. View

Gattenlohner S, Etschmann B, Riedmiller H, Muller-Hermelink H . Lack of KRAS and BRAF mutation in renal cell carcinoma. Eur Urol. 2009; 55(6):1490-1. DOI: 10.1016/j.eururo.2009.02.024. View

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

Patra K, Hay N . The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014; 39(8):347-54. PMC: 4329227. DOI: 10.1016/j.tibs.2014.06.005. View

Li Y, Guan B, Liu J, Zhang Z, He S, Zhan Y . MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma. EBioMedicine. 2019; 44:439-451. PMC: 6604878. DOI: 10.1016/j.ebiom.2019.05.041. View

Kovac M, Navas C, Horswell S, Salm M, Bardella C, Rowan A . Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nat Commun. 2015; 6:6336. PMC: 4383019. DOI: 10.1038/ncomms7336. View

Yamaguchi Y, Kamai T, Higashi S, Murakami S, Arai K, Shirataki H . Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer. BMC Cancer. 2019; 19(1):1137. PMC: 6873559. DOI: 10.1186/s12885-019-6347-0. View

Yamamoto M, Kensler T, Motohashi H . The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol Rev. 2018; 98(3):1169-1203. PMC: 9762786. DOI: 10.1152/physrev.00023.2017. View

10.

Ryoo I, Ha H, Kwak M . Inhibitory role of the KEAP1-NRF2 pathway in TGFβ1-stimulated renal epithelial transition to fibroblastic cells: a modulatory effect on SMAD signaling. PLoS One. 2014; 9(4):e93265. PMC: 3972195. DOI: 10.1371/journal.pone.0093265. View

11.

Chen F, Zhang Y, Senbabaoglu Y, Ciriello G, Yang L, Reznik E . Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep. 2016; 14(10):2476-89. PMC: 4794376. DOI: 10.1016/j.celrep.2016.02.024. View

12.

Gold R, Kappos L, Arnold D, Bar-Or A, Giovannoni G, Selmaj K . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012; 367(12):1098-107. DOI: 10.1056/NEJMoa1114287. View

13.

Fabrizio F, Sparaneo A, Trombetta D, Muscarella L . Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs. Oxid Med Cell Longev. 2018; 2018:2492063. PMC: 5872633. DOI: 10.1155/2018/2492063. View

14.

Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R . Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2015; 63(1):173-84. PMC: 4688087. DOI: 10.1002/hep.28251. View

15.

Fabrizio F, Costantini M, Copetti M, la Torre A, Sparaneo A, Fontana A . Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. Oncotarget. 2017; 8(7):11187-11198. PMC: 5355256. DOI: 10.18632/oncotarget.14492. View

16.

Ichimura Y, Waguri S, Sou Y, Kageyama S, Hasegawa J, Ishimura R . Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell. 2013; 51(5):618-31. DOI: 10.1016/j.molcel.2013.08.003. View

17.

Leshets M, Silas Y, Lehming N, Pines O . Fumarase: From the TCA Cycle to DNA Damage Response and Tumor Suppression. Front Mol Biosci. 2018; 5:68. PMC: 6068284. DOI: 10.3389/fmolb.2018.00068. View

18.

Yamada Y, Nohata N, Uchida A, Kato M, Arai T, Moriya S . Replisome genes regulation by antitumor miR-101-5p in clear cell renal cell carcinoma. Cancer Sci. 2020; 111(4):1392-1406. PMC: 7156888. DOI: 10.1111/cas.14327. View

19.

Anraku T, Kuroki H, Kazama A, Bilim V, Tasaki M, Schmitt D . Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer. Int J Mol Med. 2020; 45(2):315-323. PMC: 6984786. DOI: 10.3892/ijmm.2019.4427. View

20.

Bardella C, El-Bahrawy M, Frizzell N, Adam J, Ternette N, Hatipoglu E . Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol. 2011; 225(1):4-11. DOI: 10.1002/path.2932. View